Lithium has been studied in 108 papers since 2016: 4 trials and 44 observational studies in people, 14 in animals, 3 in cells, 42 reviews; 47 in the past year. It is an approved medicine. The newest story, Oct 7, 2026: “Starting lithium linked to lower death and dementia risks”.
Independent labs report longer fly lifespan with lithium and lower dementia risk associated with its use in people with bipolar disorder; a mouse study shows no clear lifespan effect. Human trials report cognitive benefits in amnestic mild cognitive impairment, while an observational study links longer treatment with advanced kidney disease. Some papers declare company ties.
139 findings in 64 papers from 2016 to 2026, 17 of them since April 2026
Independent labs found the same change in worms or flies and people. 38 independent labs in 17 countries; 119 trials, 2 about aging, 55 with no results posted.
“Participants in the placebo group displayed cognitive and functional decline, whereas lithium-treated patients remained stable over 2 years.”
Worms or flies and humans: replicated by independent labs. Cells and mice: a single group.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
About aging: the drug’s trials about aging. The total counts its trials for every use.
No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.
Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.
38 independent labs in 17 countries
8 findings against
119 trials, 2 about aging, 55 with no results posted
Funders: São Paulo Research Foundation and others
7 of 104 findings with company ties
Human trial4
Humans42
Animals11
Model organisms3
Cells3
Studies in people
2 studies gave lithium to people and measured what changed.
Lithium improves cognitive function in humans (25.5 vs 18.3).
“We found statistically significant differences in current mean Mini Mental State Examination scores according to previous treatment groups, with higher scores obtained the lithium group than the control group (25.5 [SD, 5.3] vs. 18.3 [SD, 10.9], p = 0.04).”
Human trialmean 13.6 years (SD, 1.1; min: 11.0, max: 15.0 years)n = 36
Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)·
Lithium improves cognitive function in humans (amnestic mild cognitive impairment) (25.5 [SD, 5.3] vs. 18.3 [SD, 10.9], p = 0.04, Cohen's d = 0.92).
“We found statistically significant differences in current mean Mini Mental State Examination score according to previous treatment group (25.5 [SD, 5.3] vs. 18.3 [SD, 10.9], p = 0.04).”
Human trialamnestic mild cognitive impairmentafter 11 to 15 yearsn = 36
Lithium is linked with lower cellular senescence in psychiatric patients on lithium carbonate therapy.
“lithium carbonate therapy inhibited GSK3β activity and mitigated senescence signaling in urinary exfoliated podocytes and was associated with preservation of kidney function.”
Humansin psychiatric patients on lithium carbonate therapyurinary exfoliated podocytes
Lithium decreases cellular senescence in experimental studies under oxidative, inflammatory, and genotoxic stress.
“Experimental studies indicate that lithium attenuates several hallmarks of cellular senescence and promotes cellular resilience under conditions of oxidative, inflammatory, and genotoxic stress.”
Reviewin experimental studies under oxidative, inflammatory, and genotoxic stress
“potential benefits on the aging process and age-related diseases of these systems, such as cardiovascular disease, osteoporosis, sarcopenia, obesity and type 2 diabetes, Alzheimer's disease, and the chronic low-grade inflammatory state known as inflammaging.”
Lithium showed no clear effect on functional state in humans.
“In contrast, no significant differences were found between the groups regarding depressive symptoms (Montgomery-Åsberg Depression Rating Scale), functional state (IQCODE, CDR-Global Score, CDR-Sum of Boxes, and FAST), or estimated time to decline in instrumental or basic activities of daily living.”
Human trialmean 13.6 years (SD, 1.1; min: 11.0, max: 15.0 years)n = 36
Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)·
Depressive symptoms
↔no changein humans1
1 study
Lithium showed no clear effect on depressive symptoms in humans.
“In contrast, no significant differences were found between the groups regarding depressive symptoms (Montgomery-Åsberg Depression Rating Scale), functional state (IQCODE, CDR-Global Score, CDR-Sum of Boxes, and FAST), or estimated time to decline in instrumental or basic activities of daily living.”
Human trialmean 13.6 years (SD, 1.1; min: 11.0, max: 15.0 years)n = 36
Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)·
Verbal fluency
↑upin humans1
1 study
Lithium improves verbal fluency in humans (34.4 vs 11.6).
“The lithium group also had better performance in the phonemic Verbal Fluency Test than the control group (34.4 [SD, 14.4] vs. 11.6 [SD, 10.10], p < 0.001).”
Human trialmean 13.6 years (SD, 1.1; min: 11.0, max: 15.0 years)n = 36
Lithium is linked with a lower risk of dementia in adults with bipolar disorder compared with valproate (HR 0.689, 95% CI 0.578-0.822; RR 0.658, 95% CI 0.556-0.778).
“Lithium use was associated with a lower risk of all-cause dementia than valproate use (207 [7.1%] vs 311 [10.8%]; Relative risk [RR], 0.658; 95% confidence interval [CI], 0.556-0.778; Hazard ratio [HR], 0.689; 95% CI, 0.578-0.822; both P<.001).”
Humansin adults with bipolar disorder compared with valproate
Lithium lowers the risk of dementia in humans (long-term lithium users).
“Large observational studies report lower dementia incidence and reduced fracture risk in long-term lithium users, together with increases in bone mineral density.”
Lithium is linked with a lower risk of Alzheimer's disease in humans (bipolar disorder or recurrent major depressive disorder) (hazard ratio = 0.48; 95% CI = 0.32-0.73; log rank p < 0.001).
“Time-to-event analysis demonstrated a lower hazard of AD diagnosis among lithium-exposed patients (hazard ratio = 0.48; 95% CI = 0.32-0.73; log rank p < 0.001).”
Humansbipolar disorder or recurrent major depressive disorderat least one year
Lithium is associated with mortality in humans (Lithium initiation compared with valproate initiation; propensity score-matched groups) (HR 0.58, 95% CI 0.53–0.63).
“Lithium initiation was associated with a lower recorded risk of all-cause mortality than valproate initiation”
Lithium is associated with functional impairment in humans (Residents of rural US counties) (Adjusted ORs 0.33–0.87).
“reduced odds of depression diagnosis (adjusted odds ratios [ORs] ranged from 0.64 to 0.88), functional impairment (adjusted ORs ranged from 0.33 to 0.87)”
HumansResidents of rural US countiesGroundwater lithium ≥30 μg/L versus <10 μg/L
Studies report lithium extends fly lifespan; a mouse study reports improved healthspan without a clear lifespan effect within tolerable doses. A human cohort and reviews link lithium with lower dementia risk, an association reported by independent groups. One registered trial concerns aging; 61 trials across uses lack posted results over a year after ending, and three of 26 papers declare company ties.
Reviews describe lithium decreasing cellular senescence under stress in experimental studies, alongside human associations with telomere length in bipolar disorder and a reduced risk of dementia and Alzheimer's disease.
Estimated five-year risks were 6.61% versus 10.65% for death and 3.51% versus 4.85% for dementia, comparing lithium with valproate.Estimated five-year risks were 6.61% versus 10.65% for death and 3.51% versus 4.85% for dementia, comparing lithium with valproate.